Delving into the Latest Updates on Ustekinumab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Anti-interleukin-12 p40 monoclonal antibody, Stellara, Sterrara

+ [13]

Target

IL-12 x IL-23

Mechanism

IL-12 inhibitors(Interleukin-12 inhibitors), IL-23 inhibitors(Interleukin-23 inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesDigestive System Disorders+ [4]

Active Indication

Colitis, UlcerativeCrohn DiseaseArthritis, Psoriatic+ [11]

Inactive Indication

DermatomyositisHidradenitis SuppurativaLupus Nephritis+ [12]

Originator Organization

Janssen Biotech, Inc.

Active Organization

Janssen Research & Development LLCJanssen-Cilag International NV

Janssen Global Services LLC

+ [8]

Inactive Organization

Centocor, Inc.Janssen-Cilag Ltd.Centocor Research & Development, Inc.

+ [3]

Drug Highest PhaseApproved

First Approval Date

EU (15 Jan 2009),

Arthritis, PsoriaticCrohn's disease, active moderateCrohn's disease, active severe+ [3]

RegulationOrphan Drug (US), Overseas New Drugs Urgently Needed in Clinical Settings (CN)

Login to view timeline

Structure/Sequence

Sequence Code 143665H

Source: *****

Sequence Code 143874L

Source: *****

the goal of this study is to compare the efficacy of ustekinumab with infliximab for the treatment of ulcerative colitis aim of the study :
1. Compare effectiveness of ustekinumab versus infliximab therapy in remission achievement in UC patients.
2. Compare safety of ustekinumab therapy versus infliximab therapy in UC
3. To asses quality of life of ustekinumab therapy versus infliximab therapy in UC patients.

Start Date15 May 2025

Sponsor / Collaborator

Helwan University

NCT06788340

/ Not yet recruitingPhase 4IIT

MOdel-Informed Precision Dosing (MIPD) of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease - An Independent Randomized Controlled Trial

The goal of this clinical trial is to investigate if dosage of Ustekinumab (UST) and Vedolizumab (VDZ) based on Model-Informed Precision Dosing (MIPD) is equally as efficient in keeping adults with Inflammatory Bowel Disease (IBD) in remission as management based on what the treating physician deems best. The main question is:
Is using pharmacokinetic-pharmacodynamic (PK-PD) models to predict the appropriate dose and dosing interval for VDZ and UST at least as effective as current practices in maintaining IBD remission.
As above mentioned the comparison-group is adults with IBD, treated with UST or VDZ, managed as the physician deems best.
Participants will:
Have blood and stool tests done, as well as answer a questionnaire 4th weekly Have their dosage frequency decided on either by the PK-model or as the physician deems best visit the clinic once every 24 weeks for checkups. Have an endoscopy done at completion of the study (if the disease is primarily located in the small intestine, MRI or capsule endoscopy will be used instead)

Start Date01 Mar 2025

Sponsor / Collaborator

Odense University Hospital

100 Clinical Results associated with Ustekinumab

Login to view more data

100 Translational Medicine associated with Ustekinumab

Login to view more data

100 Patents (Medical) associated with Ustekinumab

Login to view more data

3,377

Literatures (Medical) associated with Ustekinumab

01 Dec 2025·IMMUNOLOGIC RESEARCH

A patient with CVID-enteropathy successfully treated with ustekinumab

Article

Author: Grammatikos, Alexandros ; Marley, Fenella ; Lockett, Melanie ; Gompels, Mark

CVID (common variable immunodeficiency) is associated with a variety of gastrointestinal disorders including those mimicking Crohn's disease and ulcerative colitis. At present there is no clear trial data for the treatment of CVID enteropathy. There are no specific recommendations for treatment; however, it is commonly treated in a similar manner to inflammatory bowel disease, with corticosteroids, 5-aminosalicylates (5-ASA), azathioprine and anti-TNF therapy all being used. We describe the case of a 54-year-old with CVID-enteropathy presenting with diarrhoea and evidence of granulomatous inflammation on colonic biopsies. He was successfully treated with ustekinumab following failure/intolerance of prednisolone, 5-ASA and azathioprine. Features of CVID-enteropathy improved both clinically and histologically, with no evidence of serious treatment-related side effects.

01 Mar 2025·CLINICAL THERAPEUTICS

Treatment Persistence Among Anti-Tumor Necrosis Factor–experienced Patients With Ulcerative Colitis Switching to a Biologic With a Different Mode of Action or Cycling to Another Anti–Tumor Necrosis Factor Agent

Article

Author: Shah, Aditi ; Zhdanava, Maryia ; Boonmak, Porpong ; Kachroo, Sumesh ; Pilon, Dominic ; Godwin, Bridget ; Burbage, Sabree

PURPOSE:

In ulcerative colitis (UC), anti-tumor necrosis factor (TNF) agents often are first-line biologic therapy. Switching to a biologic with a different mode of action (ustekinumab and vedolizumab) or cycling to another anti-TNF agent (adalimumab, infliximab, and golimumab) is necessary if an initial anti-TNF fails. This study compared real-world persistence in patients with UC who switched to a biologic with a different mode of action or cycled with another anti-TNF after nonresponse to an anti-TNF.

METHODS:

Adults with UC treated with an anti-TNF, who switched or cycled (index date) between October 21, 2019, and March 02, 2022, were selected from the IQVIA PharMetrics® Plus database. Patients had ≥12 months of continuous insurance eligibility before the first anti-TNF without UC-indicated biologics or advanced therapies. During the 12 months before the index date (baseline period), patients had no other immune disorders and discontinued the first anti-TNF. Baseline characteristics were balanced using inverse probability of treatment weights. Persistence on the index biologic was defined as no therapy exposure gaps >120 days (ustekinumab, vedolizumab, and infliximab) or >60 days (adalimumab and golimumab) between days of supply. Composite end points were persistence while corticosteroid-free (<14 consecutive days of corticosteroid supply after day 90 post-index) and persistence while on monotherapy (no immunomodulators/nonindex biologics/advanced therapies). End points were assessed with weighted Kaplan-Meier and Cox proportional hazards models 12 months after the maintenance phase started.

FINDINGS:

The switch cohort included 488 patients (mean age: 41.4 years; 44.9% female), and the cycle cohort included 129 patients (mean age: 40.7 years; 43.8% female). At 12 months after the maintenance phase started, the proportions of persistent patients (switch cohort: 79.6%; cycle cohort: 64.9%) and persistent patients on monotherapy (switch cohort: 74.6%; cycle cohort: 48.0%) were significantly higher in the switch versus cycle cohort; the proportions of persistent patients while corticosteroid-free was also higher in the switch (60.1%) versus cycle cohort (49.3%) but was not significant. In the switch cohort, the rate of persistence was 1.92 times higher (hazard ratio [HR] = 1.92; 95% CI, 1.31-2.82), the rate of persistence while on monotherapy was 2.56 times higher (HR = 2.56; 95% CI, 1.86-3.53), and the rate of persistence and being corticosteroid-free was 1.31 times higher (HR = 1.31; 95% CI, 0.98-1.77) than in the cycle cohort.

IMPLICATIONS:

Patients with UC who switched from an anti-TNF agent to a biologic with a different mode of action were more persistent on treatment than patients who cycled to another anti-TNF agent. Findings may aid physicians whose patients experience treatment failure on the first anti-TNF agent.

01 Mar 2025·AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

The Impact of Family History on Clinical Presentation and Biologic Treatment Response in Patients with Psoriasis: A Multicenter Prospective Cohort Study

Article

Author: Zhong, Xiaoyuan ; Liu, Xiaoke ; Wang, Yu ; Shi, Yuling ; Ma, Rui ; Yao, Lingling ; Jiang, Yuxiong ; Huang, Dawei ; Lu, Jiajing ; Li, Ying ; Zhang, Xilin ; Xu, Shuang

BACKGROUND:

Family history (FH) of psoriasis has been implicated as a risk factor for developing psoriasis. However, whether FH also carries information on clinical presentation and treatment response to biological agents in patients with psoriasis remains unclear.

OBJECTIVE:

This prospective, multicenter observational study aimed to analyze the clinical presentation and efficacy differences between patients with psoriasis with and without a FH.

PATIENTS AND METHODS:

The SPEECH registry is an observational, multicenter, and prospective registry that has been collecting data on psoriasis treatment since November 2022. This study included adult patients diagnosed with moderate-to-severe plaque psoriasis initiating treatment with biologics, including guselkumab, secukinumab, ixekizumab, ustekinumab, and adalimumab. FH of psoriasis was identified through patient self-report in which a positive FH was defined as a first-degree relative having psoriasis. The primary outcome measures include 75% improvement in Psoriasis Area and Severity Index (PASI75) and the Physician's Global Assessment score of cleared/minimal (PGA 0/1) after 3 months of treatment. Logistic regression was employed to determine the adjusted odds ratios (aOR) and 95% confidence intervals (CI) for the achievement of response in selected outcomes for patients with a FH compared with those without a FH.

RESULTS:

The study included a total of 859 patients, of whom 22.9% had a FH of psoriasis. Patients with psoriasis who had a FH experienced an earlier onset of the disease and more severe anxiety symptoms than those without a FH. After 3 months of treatment, patients with psoriasis with a FH exhibited a higher likelihood of achieving PASI75 (aOR 1.60 [95% CI 1.02, 2.51]) and PGA 0/1 (aOR 1.54 [95% CI 1.03, 2.31]). Notably, these differences persisted after 6 months of treatment, confirming the sustained effectiveness of biologic treatments in patients with a positive FH. Further mediation analysis uncovered a significant indirect effect of FH on the treatment response to biologics through age of onset (p = 0.028), and the proportion mediated was 20.5%.

CONCLUSION:

FH of psoriasis may affect the clinical course of patients and enhance their treatment response to biologics, highlighting the importance of FH assessment in optimizing treatment outcome and guiding clinical decision of biologic selection. Future studies on biologic treatment responses in psoriasis should consider family history as a significant confounding factor.

CHINESE CLINICAL TRIAL REGISTRY:

ChiCTR2000036186.

383

News (Medical) associated with Ustekinumab

27 Feb 2025

·synapse.patsnap.com

Analysis on the Clinical Research Progress of IL-23 inhibitors

IL-23, or Interleukin-23, is a crucial cytokine that plays a significant role in the human body's immune response. It is primarily produced by activated antigen-presenting cells, such as dendritic cells and macrophages. IL-23 acts as a mediator between innate and adaptive immunity by stimulating the production of pro-inflammatory cytokines and promoting the differentiation and expansion of T-helper 17 (Th17) cells. Th17 cells, in turn, produce various cytokines that contribute to inflammation and immune responses against pathogens. However, dysregulation of IL-23 signaling has been associated with several autoimmune diseases, making it an important target for therapeutic interventions in the pharmaceutical industry. IL-23 Competitive LandscapeAccording to the data provided by Patsnap Synapse-Global Drug Intelligence Database: as of 20 Sep 2023, there are a total of 39 IL-23 drugs worldwide, from 68 organizations, covering 31 indications, and conducting 279 clinical trials. The analysis of target IL-23 reveals a competitive landscape with multiple companies actively involved in research and development. Johnson & Johnson, Alvotech Swiss AG, and AstraZeneca PLC are among the companies showing significant progress. Approved indications for IL-23 drugs include psoriasis, Crohn Disease, plaque psoriasis, colitis, ulcerative, and arthritis, psoriatic. Monoclonal antibodies and biosimilars are the most rapidly progressing drug types, indicating intense competition. The United States, European Union, and China are the leading countries in IL-23 drug development, with China showing notable progress. Overall, the target IL-23 presents a promising opportunity for the pharmaceutical industry, with a wide range of indications and potential applications. IL-23 inhibitors approved for marketing: Ustekinumab Ustekinumabis a monoclonal antibody drug that targets IL-12 and IL-23. It has been approved for use in various therapeutic areas, including infectious diseases, nervous system diseases, cardiovascular diseases, digestive system disorders, skin and musculoskeletal diseases, and immune system diseases. The drug is indicated for the treatment of colitis, ulcerative, Crohn disease, arthritis, psoriatic, psoriasis, plaque psoriasis, Takayasu arteritis, dermatomyositis, inflammatory bowel diseases, and spondylarthritis. The originator organization of Ustekinumab is Janssen Biotech, Inc. It received its first approval in Canada in December 2008. The drug has also been approved in other countries globally. In China, it has received approval as well. Ustekinumab falls under the category of overseas new drugs urgently needed in clinical settings and is also classified as an orphan drug. This indicates that the drug addresses a significant unmet medical need and is intended for the treatment of rare diseases or conditions. As a monoclonal antibody, Ustekinumab works by targeting specific proteins in the immune system, namely IL-12 and IL-23. By inhibiting these proteins, the drug helps to regulate the immune response and reduce inflammation associated with various diseases. The approval of Ustekinumab in multiple therapeutic areas highlights its versatility and potential to address a wide range of medical conditions. Its efficacy and safety profile have been evaluated through clinical trials and regulatory processes, leading to its approval for use in patients. In summary, Ustekinumab is a monoclonal antibody drug that targets IL-12 and IL-23. It has been approved for the treatment of various diseases in different therapeutic areas. The drug was first approved in Canada in 2008 and has since received approval in other countries globally, including China. Its classification as an overseas new drug urgently needed in clinical settings and an orphan drug underscores its importance in addressing unmet medical needs. Ebdarokimab Ebdarokimab is a monoclonal antibody drug that targets IL-12p40 and IL-23. It is being developed by Akeso Biopharma Co., Ltd., a pharmaceutical company specializing in biomedicine. The drug is primarily intended for the treatment of various disorders related to the digestive system, immune system, skin, and musculoskeletal system. The therapeutic areas that Ebdarokimab focuses on include digestive system disorders, immune system diseases, and skin and musculoskeletal diseases. This suggests that the drug may have potential applications in treating conditions such as plaque psoriasis, colitis, and ulcerative colitis. These diseases are characterized by inflammation and immune system dysregulation, and targeting IL-12p40 and IL-23 may help to alleviate symptoms and improve patient outcomes. Ebdarokimab has reached the NDA/BLA stage, both globally and in China. NDA stands for New Drug Application, while BLA stands for Biologics License Application. These phases indicate that the drug has undergone extensive preclinical and clinical testing and is now being submitted for regulatory approval. This suggests that Ebdarokimab has shown promising results in early studies and may have the potential to become a commercially available treatment option in the near future. Based on the available information, it can be concluded that Ebdarokimab is a monoclonal antibody drug targeting IL-12p40 and IL-23, with potential applications in the treatment of various disorders related to the digestive system, immune system, skin, and musculoskeletal system. The drug has reached the NDA/BLA stage, indicating its potential for regulatory approval and commercialization. However, further research and clinical trials are likely needed to fully evaluate the safety and efficacy of Ebdarokimab in treating specific indications such as plaque psoriasis, colitis, and ulcerative colitis. The content above comes from the network. if any infringement, please contact us to modify.

27 Feb 2025

·pmlive.com

EC approves Celltrion’s RoActemra biosimilar Avtozma for inflammatory diseases

The European Commission (EC) has approved Celltrion’s Avtozma (CT-P47), a biosimilar referencing Roche’s RoActemra (tocilizumab). The drug contains the active ingredient tocilizumab and has been authorised to treat all of RoActemra’s approved indications, including moderate to severely active rheumatoid arthritis, active systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis and giant cell arteritis. A biosimilar, according to the European Medicines Agency, is a biological medicine that is highly similar to one already approved in the EU. This means patients can expect the same safety and effectiveness from the biosimilar as they would from the reference product. Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody designed to inhibit soluble and membrane-bound interleukin‑6 receptors involved in driving inflammatory diseases. The EC’s decision on the drug was supported by a comprehensive data package and totality of evidence demonstrating Avtozma’s biosimilarity to RoActemra, Celltrion said. This included results from a late-stage trial in moderate to severely active rheumatoid arthritis, which demonstrated therapeutic equivalence of Avtozma and RoActemra in treating the chronic inflammatory disease that causes pain, swelling and stiffness in joints. Comparable and sustained efficacy results were observed up to week 52 of the study, and Avtozma was found to be well tolerated with a safety profile comparable to RoActemra. Additionally, no notable safety issues were identified following the single transition from RoActemra to Celltrion’s drug compared with maintenance groups up to week 52. Taehun Ha, senior vice president and head of Europe at Celltrion, said the approval “marks a critical step in [the company’s] mission to provide European healthcare systems with affordable, effective solutions for immunological disorders”. “By leveraging our integrated operations, we strengthen the stability of supply chains and enhance collaboration with European healthcare professionals,” he added. The approval comes just days after the EC approved Biocon Biologics’ Yesintek, an ustekinumab biosimilar referencing Johnson & Johnson’s Stelara, to treat multiple inflammatory diseases. Yesintek has been authorised to treat certain cases of plaque psoriasis, psoriatic arthritis and Crohn’s disease after demonstrating comparable safety and efficacy to the reference product.

Drug ApprovalClinical ResultBiosimilar

25 Feb 2025

·endpts.com

J&J seeks to stop Samsung Bioepis from licensing Stelara biosimilar

Johnson & Johnson is suing Samsung Bioepis for allegedly breaching the terms of a contract regarding the launch of the Korean biotech’s Stelara biosimilar. The lawsuit , filed Monday in federal district court, claims that Samsung violated a settlement agreement between the two parties by trying to sublicense the rights to a Stelara biosimilar to a private label provider. The 2023 agreement had allowed Samsung to launch its biosimilar product Pyzchiva in February this year, but barred it from sublicensing biosimilars to third parties. The action comes amid a flurry of Stelara biosimilar launches starting in January that are set to erode sales of the medicine, which has been a top-seller for J&J since 2019. Amgen’s Stelara biosimilar Wezlana was the first to launch last month. Nuvaila — Optum Rx’s biosimilar business — is selling Wezlana under a private label . The biosimilar versions come with a wide variety of list prices , from 5% off the branded price to between 86% and 90% off. J&J secured FDA approval for Stelara for the treatment of psoriasis in 2009. It later won label expansions for psoriatic arthritis, ulcerative colitis and Crohn’s disease. The IL-12/IL-23 targeting monoclonal antibody reached $10.9 billion in sales at its peak in 2023. But key patents started expiring that same year, opening the door for cheaper versions. Samsung’s partner Sandoz announced the US launch of Pyzchiva on Monday. In a statement shared with the media on Tuesday, J&J said it is seeking an injunction against Samsung for trying to sublicense “a second, additional product” to a pharmacy benefit manager’s private label distributor. The drugmaker stressed it is not trying to stop Samsung from selling Pyzchiva. Samsung declined to comment on the ongoing litigation. Teva and Alvotech’s biosimilar Selarsdi was launched last week. On Monday, Biocon Biologics launched its biosimilar Yesintek. The FDA has approved a total of seven Stelara biosimilars so far. Editor’s Note: This article was updated to add more context on Amgen’s Wezlana.

Drug ApprovalPatent InfringementPatent ExpirationBiosimilarLicense out/in

100 Deals associated with Ustekinumab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09214	Ustekinumab	L04AC05	DB05679

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Colitis, Ulcerative	AU	Janssen-Cilag Pty Ltd.	28 Jul 2009
Crohn Disease	AU	Janssen-Cilag Pty Ltd.	28 Jul 2009
Arthritis, Psoriatic	EU	Janssen-Cilag International NV	15 Jan 2009
Arthritis, Psoriatic	IS	Janssen-Cilag International NV	15 Jan 2009
Arthritis, Psoriatic	LI	Janssen-Cilag International NV	15 Jan 2009
Arthritis, Psoriatic	NO	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active moderate	EU	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active moderate	IS	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active moderate	LI	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active moderate	NO	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active severe	EU	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active severe	IS	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active severe	LI	Janssen-Cilag International NV	15 Jan 2009
Crohn's disease, active severe	NO	Janssen-Cilag International NV	15 Jan 2009
Plaque psoriasis	EU	Janssen-Cilag International NV	15 Jan 2009
Plaque psoriasis	IS	Janssen-Cilag International NV	15 Jan 2009
Plaque psoriasis	LI	Janssen-Cilag International NV	15 Jan 2009
Plaque psoriasis	NO	Janssen-Cilag International NV	15 Jan 2009
Ulcerative colitis, active moderate	EU	Janssen-Cilag International NV	15 Jan 2009
Ulcerative colitis, active moderate	IS	Janssen-Cilag International NV	15 Jan 2009

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Juvenile Idiopathic Arthritis	Phase 3	US	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	AR	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	DK	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	FR	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	DE	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	IT	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	PL	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	ES	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	TR	Janssen Research & Development LLC	30 Aug 2022
Juvenile Idiopathic Arthritis	Phase 3	GB	Janssen Research & Development LLC	30 Aug 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04549792 (CTgov)	Early Phase 1	Sjogren-Larsson Syndrome \| Ichthyosis	13	ustekinumab	qjasbsywfw(caywwlzbhg) = upvatcyxqm nekhfibrlb (wsrxfxfvtm, qdpokemlfb - evtmisacji) View more	-	12 Feb 2025
NCT04882072 (CTgov)	Phase 3	Takayasu Arteritis	14	placebo+ustekinumab (Double-blind: Placebo)	pprcbjsbmn(ejgzirfrpv) = ogwxdgcgjx hskpynnabv (gphjgvmmdw, cgnfvgfrgv - lglsrbcjmo) View more	-	02 Dec 2024
				Ustekinumab (Double-blind: Ustekinumab)	pprcbjsbmn(ejgzirfrpv) = mapppqhbjn hskpynnabv (gphjgvmmdw, jdsrfxaulq - epchoxgndm) View more
NCT04629196 (CTgov)	Phase 4	Crohn Disease	12	Ustekinumab (IV Weight-Based Induction Dose)	pkyjoqnwmm(rphjxtykzi) = kodgunwato cbjexryxse (zmxuxkvppg, fdvorsnelg - xnthgjluxh) View more	-	05 Nov 2024
				Ustekinumab (Standard Subcutaenous Dose)	pkyjoqnwmm(rphjxtykzi) = gnwwnlyzgl cbjexryxse (zmxuxkvppg, ckxkxqeawj - swdycwaghm) View more
UEGW2024	Not Applicable	Crohn Disease	-	Ustekinumab as 1st line biologic treatment	jgvhfajihs(bjtvpmapqx) = 63.9% (108/169) of patients experienced adverse events grepvsqoee (biomyogbyu ) View more	-	13 Oct 2024
				Ustekinumab as 2nd line biologic treatment
NCT03942120 (K-STAR, Pubmed \| Inflamm Bowel Dis) Manual	Not Applicable	Crohn Disease Maintenance \| Induction	464	Ustekinumab	mlaktszrnt(bfdkhisuyu) = salxmleaot qzpwaaolbz (xahufwciwn ) View more	Positive	03 Aug 2024
				Ustekinumab (At week 52 to 66)	mlaktszrnt(bfdkhisuyu) = xdjnrgcrgz qzpwaaolbz (xahufwciwn ) View more
NCT04093531 (CTgov)	Phase 1	Primary Sjögren's syndrome	12	ustekinumab	pqyokrkxgx(gotlergkvq) = kiakbxdhtb nchdxkzhrl (xplybgokwl, mjhlifapjy - pebqitokhv) View more	-	25 Jun 2024
DDW2024	Not Applicable	Colitis, Ulcerative	-	Ustekinumab	wvqorczrxj(eaewvpwooc) = bttjidjbqo imqxemwbzh (lcdakdukqk ) View more	-	21 May 2024
				Vedolizumab	wvqorczrxj(eaewvpwooc) = fjvlcicuqf imqxemwbzh (lcdakdukqk ) View more
DDW2024	Not Applicable	Crohn Disease	-	Ustekinumab	jjmipcukjz(xuhrlfvjou) = qwplyqgcgm lnnggomkun (dplvmsclub ) View more	-	20 May 2024
NCT04089345 (Pubmed \| Clin Gastroenterol Hepatol) Manual	Phase 3	Pouchitis	22	ustekinumab intravenously at baseline (∼6mg/kg)	zrfngkccet(yhmgvrzusa) = awuqrhxquu crygpvtbzz (iynkkmuzmi ) View more	Positive	14 May 2024
NCT03981744 (CTgov)	Phase 3	Dermatomyositis	51	placebo+ustekinumab (Placebo)	qexzdgkqvk(avrnhmfthu) = jyrlhiuuoo fsgknatetl (kkxcpzqrou, skjmwjoebf - pnklxubebd) View more	-	13 May 2024
				Ustekinumab (Ustekinumab)	qexzdgkqvk(avrnhmfthu) = lwlhgmbqxb fsgknatetl (kkxcpzqrou, ynvwviinfd - ggzvozstuc) View more